Allergan successfully completes Kythera acquisition
KYBELLA® first FDA-approved non-surgical injection for submental fullness bolsters Allergan’s world-class facial aesthetics portfolio
Read MoreKYBELLA® first FDA-approved non-surgical injection for submental fullness bolsters Allergan’s world-class facial aesthetics portfolio
Read MoreKlaus Hoffmann reviews the results of phase I, II, and III clinical studies using ATX-101 for the reduction of submental fat and discusses its potential use in clinical practice
Read MoreSkin laxity and fat build-up under the chin is a common concern among facial aesthetic patients. Although surgery has long been the mainstay for reducing fat in this area, which...
Read MoreTopokine Therapeutics has initiated dosing in a Phase 2, randomised controlled clinical trial of XAF5 Gel for reduction of excess submental fat, commonly referred to as ‘double chin’. XAF5 Gel...
Read More